Insilico Medicine

Insilico Medicine is developing software that uses generating models of neural networks, reinforcement training (RL), and other modern machine learning methods to create new molecular structures with specific properties. Insilico Medicine is also developing software to generate synthetic biological data, identify targets, and predict clinical trial outcomes.

The company combines two business models: the provision of services for the creation of drugs based on artificial intelligence and software through its own platform Pharma.AI, as well as the development of its own line of preclinical programs. The preclinical program is aimed at improving methods of detecting targets, creating new molecules using its own platforms.

History

2022: Attracting $13 million investment

On January 11, 2021, Shanghai Fosun Pharmaceutical, China's leading international health innovation group, and Insilico Medicine entered into a cooperation agreement to promote the discovery and development of drugs aimed at a number of different goals on a global scale using AI technology. The deal also involves investments in a company founded by a Russian.

This strategic collaboration includes joint AI-based drug research and development across four biological targets, as well as the joint development of Insilico's QPCTL program. Insilico will receive a total advance payment of $13 million for R&D cooperation projects and the joint development of the QPCTL program, potential stage payments and the share of profits from the commercialization of the QPCTL program. In addition, Fosun Pharma will make an investment in Insilico's equity.

The developer of the machine learning system created by the Russian to find new treatments raised $13 million

Insilico Medicine, founded in 2014 by CEO Alexander Zhavoronkov, is researching and developing drugs to increase life expectancy. The company uses innovative AI solutions to discover drugs and research aging, as well as deep learning technology to repurpose drugs for the treatment of aging and age-related diseases, which allows the identification of molecules that can be effective against various types of cancer, as well as metabolic, cardiovascular and central nervous system diseases.

We are pleased to enter into strategic cooperation with Insilico. Fosun Pharma is committed to promoting innovative research and development, addressing unmet clinical needs and improving drug availability. We look forward to working with Insilico to leverage the technological and clinical strengths of both companies, jointly improve the research and development of innovative drugs and benefit more patients worldwide, said Ifang Wu, Chairman and CEO of Fosun Pharma.

The collaboration is aimed at combining Insilico's comprehensive drug search platforms based on artificial intelligence and clinical development and Fosun Pharma's commercial experience to discover and develop a portfolio of new therapeutic drugs. Under the collaboration agreement, Insilico will assume responsibility for developing a preclinical candidate for the QPCTL program and advancing it to the IND stage, after which Fosun Pharma will conduct human clinical research and participate in global candidate development. In parallel, the Fosun Pharma research team will set four therapeutic targets that will be evaluated by the artificial intelligence platform Insilico and the research team responsible for advancing candidates at the IND stage.

Collaboration with Fosun Pharma, a leading pharmaceutical company, opens a new era of end-to-end drug search and development using AI, as human-machine collaboration becomes the new norm in the search and development of precision drugs. We have previously demonstrated that AI can be used to detect new targets and create new molecules that can be tested in humans in record time. Now we are working with one of the leading scientific groups in the pharmaceutical industry to bring this technology to a new level for the benefit of patients around the world, said Zhavoronkov.[1]

Notes